Purpose: To assess oncological outcomes, toxicities, quality of life (QoL) and sexual health (SH) of low-grade glioma (LGG) patients treated with pencil-beam scanning proton therapy (PBS-PT). Material and methods: We retrospectively analyzed 89 patients with LGG (Neurofibromatosis type 1;n= 4 (4.5%) patients) treated with PBS-PT (median dose 54 Gy (RBE)) from 1999 to 2022 at our institution. QoL was prospectively assessed during PBS-PT and yearly during follow-up from 2015 to 2023, while a cross-sectional exploration of SH was conducted in 2023. Results: Most LGGs (n= 58; 65.2%) were CNS WHO grade 2 and approximately half (n= 43; 48.3%) were located in the vicinity of the visual apparatus/thalamus. After a median follow-up of 50.2 months, 24 (27%) patients presented with treatment failures and most of these (n= 17/24; 70.8%) were salvaged. The 4-year overall survival was 89.1%. Only 2 (2.2%) and 1 (1.1%) patients presented with CTCAE grade 4 and 3 late radiation-induced toxicity, respectively. No grade 5 late adverse event was observed. The global health as a domain of QoL remained stable and comparable to the reference values during PBS-PT and for six years thereafter. Sexual satisfaction was comparable to the normative population. Conclusions: LGG patients treated with PBS-PT achieved excellent long-term survival and tumor control, with exceptionally low rates of high-grade late toxicity, and favorable QoL and SH.
目的：评估采用笔形束扫描质子治疗（PBS-PT）的低级别胶质瘤（LGG）患者的肿瘤学结局、毒性反应、生活质量（QoL）及性健康（SH）状况。材料与方法：我们回顾性分析了1999年至2022年间在本机构接受PBS-PT治疗（中位剂量54 Gy（RBE））的89例LGG患者（其中4例（4.5%）为1型神经纤维瘤病）。在2015年至2023年期间，于PBS-PT治疗期间及治疗后每年进行前瞻性QoL评估，并于2023年开展SH的横断面调查。结果：多数LGG（n=58；65.2%）为WHO中枢神经系统2级肿瘤，近半数（n=43；48.3%）位于视觉通路/丘脑区域。中位随访50.2个月后，24例（27%）患者出现治疗失败，其中大部分（n=17/24；70.8%）通过挽救治疗获得控制。4年总生存率为89.1%。仅2例（2.2%）和1例（1.1%）患者分别出现CTCAE 4级和3级晚期放射性毒性反应，未观察到5级晚期不良事件。作为QoL维度的整体健康状况在PBS-PT治疗期间及治疗后六年内保持稳定，且与参考值相当。性满意度与正常人群水平相近。结论：接受PBS-PT治疗的LGG患者获得了优异的长期生存和肿瘤控制效果，高级别晚期毒性反应发生率极低，且生活质量和性健康状况良好。
肿瘤(癌症)患者之家